Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Amazon

Visa

It's time to put your money to work in brand-name companies with clear-cut competitive advantages.

Have $5,000? Here Are the 5 Megacap Stocks Smart Investors Are Buying

Teladoc

The COVID-19 outbreak won’t hurt these healthcare giants.

2 Companies That Will Report Stellar First-Quarter Results

AbbVie

Pfizer

The time is right and the price is right to buy these big pharma stocks.

3 Top Pharma Stocks to Buy in April

Bristol-Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bristol-Myers (BMY) Upgraded to Buy: Here's Why

Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.

Bristol Myers' Applications for Opdivo-Yervoy Combo Accepted

Pharmaceutical company Bristol Myers advanced in 2019 despite shareholder opposition to its Celgene buyout.

The No. 1 Pharma Company Nabbed A Key Approval — But Is It A Buy?

Amgen

Gilead Sciences

Merck

Sanofi

Track the latest trends and leading stocks in the biotech and pharmaceutical industries.

Biotech Stocks To Watch And Pharma Industry News

Mastercard

Three very different stocks with one thing in common -- tremendous growth prospects.

Got $3,000 to Invest? These 3 Stocks Could be Just What You're Looking For.

Acceleron Pharma

Bristol Myers (BMY) and Acceleron received FDA nod for the label expansion of Reblozyl for MDS patients who require RBC transfusions, failing an erythropoiesis stimulating agent.

Bristol Myers/Acceleron's Reblozyl Label Expansion Gets FDA Nod

Celgene

Reblozyl recently became the first treatment for adults with lower-risk myelodysplastic syndromes.

Former Celgene Drug Earns a Key Approval for Bristol Myers Squibb

Bristol-Myers Squibb: A Great Buy After The Pullback

Avid Technology

DaVita

eBay

TEGNA

Dodge the COVID-19 pandemic by investing in these high earnings yield stocks.

Coronavirus-Led Volatility Rises: 5 High Earnings Yield Picks

Amcor Plc

Rocky Brands

Top Ranked Income Stocks to Buy for April 2nd

With the coronavirus pandemic pushing stock prices to historic lows, there are plenty of promising companies to invest in today.

Top 3 Healthcare Stocks to Buy Right Now

Bristol-Myers Squibb (BMY) closed the most recent trading day at $54.86, moving -1.58% from the previous trading session.

Bristol-Myers Squibb (BMY) Stock Moves -1.58%: What You Should Know

Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.

Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA

Eli Lilly

Moderna

Vertex Pharmaceuticals

Postponed clinical trials might mean a longer time-to-market for certain drugs.

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Johnson & Johnson

Based on historical performance, Johnson & Johnson (NYSE: JNJ) appears to be less attractive compared to Bristol-Myers Squibb in the current crisis. The current coronavirus crisis will likely impact pharmaceutical companies on two fronts, 1.

Is Johnson & Johnson A Better Bet Compared To Bristol-Myers Squibb After 15% Decline?

Abbott Labs

AstraZeneca

One thing has become increasingly obvious as the weeks have passed since the coronavirus threat entered the daily lexicon.

Why Big Pharmaceutical Stocks May Be the Best Place for Worried Investors Now

Genfit - ADR

Intercept Pharma

Madrigal Pharmaceuticals

Novartis

PTC Therapeutics

Roche Holding AG

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Intercept Pharmaceuticals Inc.

FDA Decisions on 5 Drugs Expected in 2nd Quarter

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes?

Are You Looking for a High-Growth Dividend Stock? Bristol-Myers Squibb (BMY) Could Be a Great Choice

Biogen

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Drug developers took center stage as the world looks to these companies to deliver an answer to COVID-19.

4 Reasons Drug Stocks Are a Buy Right Now

Intuitive Surgical

Profitable. Great revenue and earnings growth.

My Top Healthcare Stocks to Buy in the Market Crash

Apple

Cisco Systems

Ford Motor Company

Alphabet

Microsoft

Oracle

As the U.S. economy starts to shut down, cash is king. It is obvious how important this is when airlines need billions of dollars of aid from the government.

The 10 American Companies With the Most Cash

Pipeline and products at these three pharmaceutical companies mean long-term revenue growth once current market turmoil has passed.

News for Bristol-Myers Stock (BMY)